GlycoMimetics Inc reports results for the quarter ended in September - Earnings Summary

Crescent Biopharma

03/11/2023 13:32

* GlycoMimetics Inc  GLYC.OQ  reported a quarterly adjusted
loss
of 14 cents​​ per share for the quarter ended in September,
higher than the same quarter last year, when the company
reported EPS of -16 cents.  The mean expectation of
three analysts for the quarter was for a loss of 14 cents per
share. Wall Street expected results to range from -15 cents
to -14 cents per share.
    * Reported revenue was zero​; analysts expected zero. 
    * GlycoMimetics Inc's reported EPS for the quarter was a
loss
of 14 cents​.
    * The company reported a quarterly loss of $9.2 million.
    * GlycoMimetics Inc shares had fallen by 14.0% this
quarter and
lost 57.4% so far this year.

FORECAST CHANGES
    * The mean earnings estimate of analysts was unchanged in
the last
three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.

RECOMMENDATIONS
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 3 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 
    * The average consensus recommendation for the biotechnology
&
medical research peer group is also "buy"

Wall Street's median 12-month price target for GlycoMimetics Inc
is $5.50 
This summary was machine generated from LSEG data November 3 at
01:31 p.m. UTC. ​All figures in US dollars unless otherwise
stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Sep. 30 2023      -0.14          -0.14          Met
 Jun. 30 2023      -0.18          -0.13          Beat
 Mar. 31 2023      -0.17          -0.17          Met
 Dec. 31 2022      -0.17          -0.19          Missed